AVANIR Pharmaceuticals to Present at 2004 Top Performers of the Amex Online Conference

SAN DIEGO--(BUSINESS WIRE)--March 11, 2005--AVANIR Pharmaceuticals (AMEX:AVN) announced today its participation in the online 2004 Top Performers of the Amex investor conference to be held on March 16, 2005. The webcast event is being sponsored by the American Stock Exchange and features 15 of the top performing Amex-listed companies for 2004.

AVANIR's President and Chief Executive Officer Dr. Gerald J. Yakatan will present its investment story and share the Company's success in 2004 on March 16, 2005 at 11:00am Eastern time. For a complete schedule, or to register to attend the conference, please contact Erika Levy of the Amex IR Alliance at (212) 896-1208 or elevy@kcsa.com.

AVANIR Pharmaceuticals is a drug discovery and development company focused on treatments for chronic diseases. Our product candidates address therapeutic markets that include central nervous system and cardiovascular disorders, inflammation, and infectious disease. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The Company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.


    CONTACT: AVANIR Pharmaceuticals
             Investor Relations
             Patrice Saxon, 858-622-5202
             psaxon@avanir.com

    SOURCE: AVANIR Pharmaceuticals